Cargando…

Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study

Real-world data showed that ustekinumab is an effective treatment for Crohn’s disease for up to 52 weeks. Yet, long-term effectiveness and safety outcomes beyond 52 weeks are limited. This study aimed to evaluate the corticosteroid-free clinical remission for up to 104 weeks. Secondary aims were foc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Pepijn W.A., van Caem, Mark, West, Rachel L., Russel, Maurice G.V.M, Jansen, Jeroen M., Römkens, Tessa E.H., Hoentjen, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2022
Materias:	Original Articles: Gastroenterology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935642/ https://www.ncbi.nlm.nih.gov/pubmed/36708296 http://dx.doi.org/10.1097/MEG.0000000000002506

Ejemplares similares

De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
por: Thomas, Pepijn W. A., et al.
Publicado: (2022)

Immediate Infusion Reaction to Intravenous Ustekinumab in Three Crohn’s Disease Patients: A Case Report and Review of the Literature
por: Thomas, Pepijn W A, et al.
Publicado: (2020)

Inflammatory bowel disease patients provide reliable self‐reported medical information: A multicentre prospective pharmacovigilance monitoring system
por: Thomas, Pepijn W. A., et al.
Publicado: (2020)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study
por: Thomas, Pepijn W A, et al.
Publicado: (2022)

Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
por: Thomas, Pepijn W. A., et al.
Publicado: (2021)

Clinical Outcomes of Ustekinumab in Inflammatory Bowel Disease
por: Gara, Sirisha K, et al.
Publicado: (2023)

Ustekinumab Trough Concentrations Are Associated with Biochemical Outcomes in Patients with Crohn’s Disease
por: Straatmijer, Tessa, et al.
Publicado: (2023)

Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry
por: Giraud, Eline L., et al.
Publicado: (2021)

Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study
por: Biemans, Vince B C, et al.
Publicado: (2020)

Long‐term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease
por: Shiga, Hisashi, et al.
Publicado: (2022)

Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
por: af Björkesten, Clas-Göran, et al.
Publicado: (2020)

Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study
por: Smits, L J T, et al.
Publicado: (2020)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis
por: Gheorghe, Cristian, et al.
Publicado: (2019)

Hepatocellular Carcinoma in a Patient With Crohn’s Disease
por: Hokama, Akira, et al.
Publicado: (2021)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

An Unusual Presentation of Crohn’s Disease and Primary Sclerosing Cholangitis
por: Ekanayake, Lakmal S, et al.
Publicado: (2022)

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study
por: Asscher, Vera E. R., et al.
Publicado: (2020)

Acute Intestinal Invagination: An Exceptional Method of Revealing Crohn’s Disease
por: Jabi, Rachid, et al.
Publicado: (2021)

Macroscopic to Microscopic – A Case of Crohn’s Disease Progressing to Collagenous Colitis
por: Hussain, Murtaza Shabbir, et al.
Publicado: (2021)

Wernicke’s Encephalopathy in a Patient With Crohn’s Disease: A Case Report
por: Adamou, Fatima, et al.
Publicado: (2023)

A Challenging Case of Metastatic Crohn's Disease Without Gastrointestinal Manifestations
por: Pereira, Ana S, et al.
Publicado: (2023)

Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2022)

Meckel’s Diverticulum Charading as Crohn’s Disease: A Single-Institution Case Series
por: Eng, Nina L, et al.
Publicado: (2023)

Identifying Visceral Kaposi Sarcoma (KS): A Responsibility to Avoid Anchoring on the Diagnosis of a Crohn’s Flare
por: Seltzer, Emily S, et al.
Publicado: (2023)

Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018)

Helicobacter pylori is Associated with Less Fistulizing, Stricturing, and Active Colitis in Crohn’s Disease Patients
por: Fialho, Andre, et al.
Publicado: (2019)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2021)

Atypical Clinical Presentation of Crohn’s Disease as Diffuse Abdominal Lymphadenopathy and Venous Thrombosis: A Difficult to Diagnose Case
por: Raza, Ahmad, et al.
Publicado: (2019)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Clinical and Histologic Remission in an Adult Crohn’s Disease Patient Following the Specific Carbohydrate Diet and Its Impact on Healthcare Costs
por: Arjomand, Ali, et al.
Publicado: (2022)

A Pilot, Prospective, Randomized-Controlled Study to Evaluate the Efficacy and Safety of Arsha Hita™ in the Treatment of Anal Fissures
por: B. J., Gopikrishna, et al.
Publicado: (2023)

Rapid Resolution of Vulvar Crohn's Disease With Ustekinumab
por: Stoleru, Gianna, et al.
Publicado: (2020)

Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Prospective randomised controlled trial of adults with perianal fistulising Crohn’s disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol
por: Gu, Bonita, et al.
Publicado: (2021)

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
por: Sandborn, W. J., et al.
Publicado: (2018)

A prospective study comparing patient-reported outcomes in Crohn’s disease
por: Hoekman, Daniël R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25ssl3qccc7opthnemnd3d8c4p